ConCallIQ
Go Pro
DRREDDY Diversified 22 Jan 2025

Dr. Reddy's Laboratories Limited — Q3 FY25

Dr.

neutral medium
Compare with...
Revenue ₹8,359 Cr +16%
EBITDA ₹2,298 Cr +9%
PAT ₹1,413 Cr +2%
EBITDA Margin 27.5% -176bps
Duration
Read Time 1 min read

✓ Verified against BSE filing

Delivery score0%
Due this quarter3
Delivered0
Missed3

Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.

Q2 FY25

SG&A spend to be 27.5%-28% of sales for FY25

Management expects SG&A as a percentage of sales to be in the range of 27.5%-28% for the full fiscal year.

Missed

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

heuristic_v1
Q2 FY25

R&D spend to be 8.5%-9% of sales for FY25

Management expects R&D investment to be in the range of 8.5%-9% of sales for the full fiscal year.

Missed

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

heuristic_v1
Q2 FY25

Normalized ETR around 25% for FY25

Management expects the normalized effective tax rate to be around 25% for the fiscal year.

Missed

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

heuristic_v1